Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Angiotensin II (Ang II) plays a key role in cardiovascular diseases, including hypertension and heart failure.
• Liraglutide, a GLP-1 receptor agonist, demonstrates efficacy in treating cardiovascular disorders.
• Existing treatments often focus on glycemic control, necessitating broader therapeutic strategies.

Purpose of the Study:

• To review experimental evidence on liraglutide's cardioprotective effects.
• To elucidate mechanisms by which liraglutide counteracts Angiotensin II-induced cardiac damage.
• To assess liraglutide's impact on oxidative stress, vascular dysfunction, and cardiac remodeling.

Main Methods:

• Compilation of recent experimental outcome-based studies.
• Analysis of liraglutide's effects on Angiotensin II and pressure overload models.
• Investigation of molecular pathways involved in liraglutide's cardioprotection.

Main Results:

• Liraglutide inhibits Angiotensin II-mediated oxidative stress and vascular endothelial dysfunction.
• It effectively reduces hypertension, cardiac fibrosis, and left ventricular hypertrophy.
• Evidence supports liraglutide's role in preventing heart failure progression.

Conclusions:

• Liraglutide provides significant cardiovascular protection against deleterious effects of Angiotensin II and pressure overload.
• Its mechanisms involve reducing oxidative stress, improving vascular function, and preventing cardiac remodeling.
• Liraglutide is a valuable add-on therapy for managing diverse cardiovascular diseases.